MR spectroscopy, S100B protein and NSE analysis as early predictors of hypoxic ishaemic encephalopathy  by Noaman, A. et al.
The Egyptian Journal of Radiology and Nuclear Medicine (2013) 44, 309–320Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comREVIEWMR spectroscopy, S100B protein and NSE analysis
as early predictors of hypoxic ishaemic encephalopathyA. Noaman, R. Elshafey *, A. Al-Shahawy, M. Rowisha, M. El-Batch,
A. Fakhr EldinRadiodiagnosis, Pediatric and Biochemistry Departments, Tanta University Hospital, EgyptReceived 16 December 2012; accepted 14 January 2013
Available online 14 March 2013A
hy
na
en
*
G
E-
Pe
N
03
OpKEYWORDS
MR Spectroscopy;
Hypoxic ischemic
encephalopathy;
S100B;
NSEbbreviations: Cho, Choline;
poxic ischemic encephalopa
nce spectroscopy; NAA, N
olase
Corresponding author. Addr
harbia, Egypt. Tel.: +20 40
mail address: drrashaelshafe
er review under responsibility
uclear Medicine.
Production an
78-603X  2013 Egyptian So
en access under CC BY-NC-ND liCr, Crea
thy; 1HM
-acetylasp
ess: Tanta
2211164;
y@yahoo
of Egyp
d hostin
ciety of
httcense.Abstract Aim of work: The aim of this work is to assess S100B protein, neuron speciﬁc enolase
and magnetic resonance spectroscopy as biochemical and imaging ﬁndings in neonatal hypoxic
ischemic encephalopathy.
Methods: This prospective study on 30 full-term neonates suffering from HIE who were attendants
of the Neonatology Unit of Pediatric Department and Radiodiagnosis Department of Tanta Uni-
versity Hospital. Duration of the study extended from June 2010 to June 2012.
Results: Thirty patients (16 males and 14 females), HIE group classiﬁcation according to Lac/Cr
ratio in MRS to three groups: Groups – group I: where Lac/Cr < 0.5, group II: where Lac/Cr
0.5–1.5 and group III: where Lac/Cr > 1.5.
1HMRS group I contained 17 patients (15 patients were present in Sarnat stage I and two patients
were present in Sarnat stage II). Group II contained nine patients (all patients were present in Sar-
nat stage II). Group III contained four patients (all patients were present in Sarnat stage III).
Serum level of S100B protein and NSE were signiﬁcantly higher in the HIE group than control
group also serum level of S100B protein and NSE in HIE stage III was signiﬁcantly higher than
control, HIE stage I and stage II.tine; Glx, Glutamine; HIE,
RS, proton magnetic reso-
artate; NSE, neuron-speciﬁc
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310 A. Noaman et al.Conclusion: 1HMRS is a useful tool for evaluating the severity and prognosis of HIE noninvasive-
ly. Higher lactate/Cr ratio in basal ganglia and thalamus predict the poor prognosis of neonates.
Serum level of S100B protein and NSE has an important meaning in adjuvant diagnosing and rul-
ing out diagnosis of early HIE and prognosis of birth asphyxia.
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Hypoxic-ischemic encephalopathy describes the abnormal neu-
rological state occurring in a newborn infant following a sig-
niﬁcant hypoxic-ischemic insult. The insult may occur
antenatally, intrapartum or less commonly postnatally (1).
Conventional MRsequences however are often normalwith-
in ﬁrst hours after ischemic insult. This provides overlaps with
the narrow therapeutic window during which neuroprotective
interventionwill most likely be effective. Therefore, the develop-
ment and application of neuroimaging techniques sensitive to
the very early changes of brain ischemia is desirable (2).
Magnetic resonance spectroscopy can provide early supple-
mentary prognostic information in neonatal encephalopathy
and aids diagnosis of metabolic disorder (3).
The optimal timing for MRS appears to be toward the end
of the ﬁrst week after birth. However, at this time most of the
newborns with perinatal asphyxia are still clinically unstable
because of cardiovascular or multisystem dysfunction and fre-
quently mechanical ventilation that does not permit magnetic
resonance imaging evaluation (4).
In the neonatal period (days 1–30) themetabolite ratio of lac-
tate to N-acetyl aspartate (Lac/NAA), most frequently mea-
sured in the basal ganglia and thalamus region where
abnormalities are often seen on MRI. Changes in brain metab-
olism following asphyxia have generally been assessed in terms
of ratios of metabolites such as Lac/Cr, Cho/Cr and NAA/Cr,
Lac/NAA (5).
The elevated levels of brain Lac following transient hypox-
ia–ischemia is thought to be due to overproduction and/or
underutilization of Lac or a change in cellular redox equilib-
rium in the tissue itself (5).1.1. 1HMRS grouping
According to the difference of the mean value of Lac/Cr, cor-
related with MR imaging and clinical symptoms, HIE neo-
nates were divided into three groups: group I was the value
of Lac/Cr lesser than 0.5; group II was the value between 0.5
and 1.5; group III was the value greater than 1.5 (6).
However, in many cases these advanced imaging modalities
are not available for the study of neonates with HIE, within
the ﬁrst days of life in neonatal intensive care units. So several
biochemical markers (brain-speciﬁc creatine kinase, glial ﬁbril-
lary acidic protein, neuron-speciﬁc enolase [NSE] and protein-
S) in the blood or cerebrospinal ﬂuid have been investigated in
infants with perinatal asphyxia (7,8).
Neuron speciﬁc enolase is known as the neuronal marker
of cell cytoplasm and dendrites in both the rodent and the
human brain. Average brain levels of NSE are 12,500 ng/
mg protein in rats and 16,500 ng/mg protein in humans.
NSE accounts for 1.5% of total soluble protein content in
the CSF (9).
The presence of elevated NSE values in the blood after peri-
natal asphyxia can be a sensitive indicator of conspicuous
brain damage. The combined information provided by the
severity of the encephalopathy together with the blood NSE
values has shown a high predictive value for neurological out-
come (10).
The S100B is a member of multigenic family of calcium-
modulated proteins (S100 proteins), mostly of low molecular
mass (10,000 Da), that were ﬁrst identiﬁed as protein fraction
detectable in the brain but not in nonneural extracts and called
S100 because of their solubility in a 100% saturated solution
with ammonium sulfate (11).
Table 1 Sarnat and Sarnat classiﬁcation of HIE group.
Stage I Stage II Stage III Total
HIE
N 15 11 4 30
% 50 36.7 13.3 100
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This study was conducted on 30 full-term neonates suffering
from HIE who were attendants of the Neonatology Unit of
Pediatric and Radiodiagnosis Departments of Tanta Univer-
sity Hospital. Duration of the study extended from June
2010 to June 2012.
2.1. Inclusion criteria
Infants suffering from symptoms and signs of HIE according
to Sarnat and Sarnat Classiﬁcation (12).
2.2. Exclusion criteria
– Preterm infants (<37 weeks).
– +ve consanguinity.
– Central nervous system or cardiac malformation.
– Intrauterine infection.
– Congenital metabolic disorders.
– Maternal drug addiction.
2.3. Control group
Ten healthy full-term neonates served as a control group.
All neonates were protected by a Perspex pod. Throughout
the examination, neonates were supervised by an experienced
neonatal pediatrician. Pure oxygen breathing was maintained
in neonates with HIE throughout the scanning procedure to
ensure the security of the neonate with HIE during MR
examination.
All MR imaging and 1HMRS studies were performed using
a 1.5 T system (Signa; GE Medical Systems, Milwauee, WI,
USA) with a quadrature head coil. The routine imaging studies
included multiplanar T2-weighted fast spin-echo (4000/126/2)
with an echo train length of eight sequences.
Optimal water resonance suppression was achieved. The
parameters used were 2000/270, 192 acquisitions, a spectral
width of 2500 Hz, and 2048 data points for all patients. In
all patients, MR spectra were obtained with a TE of 144 with
additional TE 35. The acquisition time for each sequence was
7 min 54 s.
Fast spin-echo images were transverse T2-weighted MR
images. 1HMRS was performed by a multivoxel long-echo
(TE, 144 ms) point-resolved spatially localized spectroscopy.
The areas of interest in all neonates were the basal ganglia, thal-
amus, and a portion of the third and lateral ventricles. The basal
ganglia and thalami are most sensitive to the effects of acute an-
oxia. The section thickness was 20 mm, and the anterior-to-pos-
terior and right-to-left dimensions were 30 · 30 mm.
Metabolites of biologic importance, such as N-acetylaspar-
tate (NAA), Choline (Cho), Creatine (Cr), and Lactate (Lac)
and Glutamine (Glx) were detected by this technique.
2.4. Quantitative analysis of metabolite
The multivoxel MRS data were processed by the spectroscopic
analysis package on the workstation. The resonances of main
metabolites were quantiﬁed as follows: the Glx-a peak at2.1–2.5 ppm, the NAA peak at 2.02 ppm, the Cr peak at
3.02 ppm, the Cho peak at 3.20 ppm, and the Lac doublet at
1.33 ppm.
Total creatine was used as a 1HMRS spectroscopic refer-
ence metabolite because of its relative stability after hypox-
ia–ischemia and better reﬂection of deranged energy
metabolism. The ratio of NAA/Cr, NAA/Cho, Cho/Cr and
Lac/Cr was measured.
NAA, Cho, Creatine were detected at long TE while Lac-
tate and Glx were detected at short TE.
2.5. MRS grouping
The results of MRS were divided into three groups according
to Lac/Cr as the following:
– Group I was the value of Lac/Cr lesser than 0.5.
– Group II was the value of Lac/Cr between 0.5 and 1.5.
– Group III was the value of Lac/Cr greater than 1.5.
3. Results
This study was conducted on 30 full-term neonates suffering
from HIE who were attendants of the Neonatology Unit of
Pediatric Department of Tanta University Hospital and Ten
healthy full-term neonates served as a control group.
All cases followed up clinically and neurologically for 6
months to assess the prognosis of HIE.
Sarant and Sarnat classiﬁcation of HIE group: Stage I con-
tained 15 patients (50%), stage II contained 11 patients
(36.7%) and stage III contained four patients (13.3%) (Table 1).
HIE group classiﬁcation according to Lac/Cr: 1HMRS
group I contained 17 patients (15 patients were present in Sar-
nat stage I and two patients were present in Sarnat stage II).
Group II contained nine patients (all patients were present in
Sarnat stage II). Group III contained four patients (all patients
were present in Sarnat stage III) (Tables 2 and 3).
The mean Lac/Cr was 0.38 ± 0.15, 0.79 ± 0.30 and
2.6 ± 41 in stages I, II, and III, respectively compared to
0.12 ± 0.08 in the control group. The difference was statisti-
cally signiﬁcant (P= 0.001). Also Lac/Cr was signiﬁcantly
higher in HIE stage III than control, HIE stages I and II
(P= 0.001, 0.002 and 0.002) (Table 4).
The mean NAA/Cr in HIE stages I and III were
1.09 ± 0.04, 0.86 ± 0.18 and 0.48 ± 0.12, respectively com-
pared to 1.16 ± 0.08 in the control group. The difference
was statistically signiﬁcant (P= 0.001). Also NAA/Cr in
HIE stage III was signiﬁcantly lower than control, HIE stage
I and HIE stage II (P= 0.001, 0.001 and 0.004) (Table 5).
The mean NAA/Cho in HIE stages I, II and III were
0.39 ± 0.03, 0.26 ± 0.06 and 0.18 ± 0.05 versus 0.47 ± 0.03
in the control group. The difference was statistically signiﬁcant
Table 2 HIE group classiﬁcation according to Lac/Cr.
Group I Group II Group III Total
MRS
N 17 9 4 30
% 56.7 30 13.3 100
Table 3 Comparison between Sarnat clinical staging and
1HMRS grouping.
Stage I Stage II Stage III Total
HIE
N 15 11 4 30
% 50 36.7 13.3 100
MRS
N 17 9 4 30
% 56.7 30 13.3 100
312 A. Noaman et al.(P= 0.001). Also the mean NAA/Cho in HIE stage III was
signiﬁcantly lower than control, HIE stage I and HIE stage
II (P= 0.001, 0.002 and 0.008) (Table 6).
The mean Cho/Cr in HIE stages I, II and III were
2.52 ± 0.16, 2.93 ± 0.36 and 3.41 ± 0.41, respectively com-
pared to 1.31 ± 0.21 in the control group. The difference
was statistically signiﬁcant (P= 0.04). Also Cho/Cr in HIE
stage III was signiﬁcantly higher than control and HIE stage
I (P= 0.009 and 0.045). And no difference between HIE stage
III and stage II (Table 7).
The mean level of serum NSE (ng/ml) in the HIE group was
81.7 ± 23.48 while in HIE stages I, II and III were
28.66 ± 5.26, 121.72 ± 33.99 and 167.2 ± 29.64 ng/ml,
respectively compared to 12.99 ± 1.96 ng/ml in the control
group. The difference was statistically signiﬁcant
(P= 0.001). Also serum level of NSE in HIE stage III was sta-
tistically and signiﬁcantly higher than control, HIE stage I and
stage II (P= 0.001, 0.001, and 0.003, respectively) (Table 8).
The mean serum level of S100B protein of the HIE group
was 3.27 ± 1.05 while in HIE stages I, II and III were
0.71 ± 0.36, 5.82 ± 1.72 and 8.86 ± 0.54 ng/ml, respectively
compared to 0.048 ± 0.04 ng/ml in the control group. The dif-
ference was statistically signiﬁcant (P= 0.001). Also serum le-
vel of S100B protein in HIE stage III was signiﬁcantly higher
than control, HIE stages I and II (P= 0.001, 0.002 and
0.003, respectively) (Table 9).
As regards biochemical marker the highest sensitivity and
speciﬁcity were observed for S100B protein with the sensitivity
and speciﬁcity of 92.3% and 90.5%, respectively versus 91.2
and 87.4 to NSE. PPV and NPP also were higher for S100B
protein than those of NSE 88.9 and 91.6 versus 85.7 and
79.2, respectively. As regards MRS peak metabolite ratios
the highest sensitivity was for Lac/Cr 88.2 versus 84 and 82.5
for NAA/Cr and NAA/Cho, respectively. While the highest
speciﬁcity for NAA/Cho was 83.58 versus 76.9 and 80.6 for
Lac/CR and NAA/Cr, respectively. Highest PPV was for
Lac/Cr and NAA/Cho 81.63 versus 75.8 for NAA/Cr. Lastly
NPP was the highest for Lac/Cr 86.3 versus 85.6 and 79.6
for NAA/Cr and NAA/Cho, respectively (Table 10).
3.1. Cases
Unenhanced axial T1WI (A) and axial T2WI (B), show normal
progress of myelination with a normal signal intensity of the
posterior limb of internal capsule by T1WI, and decreased
its signal intensity by T2WI relative to basal ganglia and
thalamus.
Multivoxel 1HMRS picture (C), and MRS spectrum (D) –
(TE 144), as well as multivoxel 1HMRS picture (E), and
MRS spectrum (F) – (TE 35) at the basal ganglia show normal
Lac/Cr, NAA/Cr, NAA/Cho and Cho/Cr ratios. (Lac/
Cr = 0.16, NAA/Cr = 1.2, NAA/Cho = 0.55 and Cho/
Cr = 1.52) (Fig. 1).
Unenhanced axial T1WI (A) shows a slightly increased sig-
nal intensity of basal ganglia with a normal signal intensity of
both thalami. Axial T2WI (B) shows edematous changes of the
white matter appear as hyperintensities mainly in frontal and
occipital lobes with a normal hypointense signal of the poster-
ior limb of the internal capsule corresponding to normal pro-
gress of myelination.
Multivoxel 1HMRS picture (C), and MRS spectrum (D) –
(TE 144), as well as Multivoxel 1HMRS picture (E), andMRS spectrum (F) – (TE 35) at the basal ganglia show de-
creased peaks of NAA and slightly increased Cho, lactate,
and Glx peaks which denote hypoxic ischemic brain injury.
Moreover, MRS revealed decreased NAA/Cr, and NAA/Cho
ratios with increased Lac/Cr ratios in comparison to normal
(Lac/Cr = 0.45, NAA/Cr = 1.0 and NAA/Cho = 0.42).
Mild elevation of Lac/Cr and decrease NAA/Cr denote a
mild grade of HIE (Fig. 2).
Unenhanced axial T1WIs (A and B) show cortical and peri-
ventricular curvilinear hyperintensities with punctuate hyper-
intense foci in the basal ganglia with small left occipital
subgalial acute hematoma.
Axial T2WIs (C and D) T2WI show brain edema of the
white matter in the bilateral frontal and parietal lobes. Mini-
mal hemorrhage in basal ganglia was detected, and lack of
clarity of hypointensity derived from myelinization of the pos-
terior limb of the internal capsule, with prominent subarach-
noid spaces. Moreover, early subacute subgalial hematoma
in the left parieto-occipital region is seen.
Multivoxel 1HMRS picture (C), and 1HMRS spectrum (D)
– (TE 144), 1HMRS spectrum (E) – (TE 35) at the basal gan-
glia show decreased peaks of NAA and elevated peaks of Cho,
Lac, and Glx. Furthermore, MRS reveals decreased ratios of
NAA/Cr and NAA/Cho with increased Lac/Cr ratio in com-
parison to normal ratios (Lac/Cr = 0.8, NAA/Cr = 0.75,
NAA/Cho = 0.3).
The increased Lac/Cr ratio and decreased NAA/Cr repre-
sents moderate grade of HIE (Fig. 3).
Unenhanced axial T1WIs (A and B) show curvilinear corti-
cal hyperintensities with areas of increased signal intensity in
both basal ganglia and thalami. Decreased signal intensity of
the posterior limb of internal capsule is seen denoting poor
myelination.
Axial T2WI (C) shows a decreased signal intensity of the
brain cortex, both basal ganglia and thalami with hyperintense
signal of the posterior limb of internal capsule, indicative of
poor myelination with hypoxic ischemic injury. Axial
T2*GRE image (D) shows punctuate areas of abnormal low
signal intensity in both thalami and putamen indicating punc-
tate areas of hemorrhage which exhibit hyperintense signal by
T1WI and hypointense signal by T2WI.
Table 4 The mean Lac/Cr in HIE and control groups.
Lac/Cr Stage I Stage II Stage III Control
Mean 0.38 0.79 2.60 0.12
±SD 0.15 0.30 0.41 0.08
P value 0.001*
Stage I & II Stage I & III Stage II & III Stage I & control Stage II & control Stage III & control
Scheﬀe test
0.004* 0.002* 0.002* 0.014* 0.002* 0.001*
* Signiﬁcance P< 0.05
Table 5 The mean NAA/Cr in HIE and control groups.
NAA/Cr Stage I Stage II Stage III Control
Mean 1.09 0.86 0.48 1.16
±SD 0.04 0.16 0.12 0.08
P value 0.001*
Stage I & II Stage I & III Stage II & III Stage I & control Stage II & control Stage III & control
Scheﬀe test
0.003* 0.001* 0.004* 0.010* 0.001* 0.001*
* Signiﬁcance P< 0.05
Table 6 The mean NAA/Cho in HIE and control groups.
NAA/Cho Stage I Stage II Stage III Control
Mean 0.39 0.26 0.18 0.47
±SD 0.03 0.06 0.05 0.03
P value 0.001*
Stage I & II Stage I & III Stage II & III Stage I & control Stage II & control Stage III & control
Scheﬀe test
0.005* 0.002* 0.008* 0.012* 0.001* 0.001*
* Signiﬁcance P< 0.05
Table 7 The mean Cho/Cr in HIE and control groups.
Cho/Cr Stage I Stage II Stage III Control
Mean 2.52 2.93 3.41 1.31
±SD 0.16 0.36 0.41 0.21
P value 0.047*
Stage I & II Stage I & III stage II & III Stage I & control Stage II & control Stage III & control
Scheﬀe test
0.174 0.045* 0.059 0.018* 0.051 0.009*
* Signiﬁcance P< 0.05
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(TE 144), as well as multivoxel 1HMRS picture (G), and
MRS spectrum (H) – (TE 35) at the basal ganglia show de-
creased peaks of NAA and elevated peaks of Cho, Lac and
Glx due to hypoxia-ischemia with a marked increase of myo-
inositol level in short TE sequences with an increase in lipids
due to necrosis. Furthermore, the NAA/Cr and NAA/Cho ra-
tios are markedly decreased with signiﬁcantly elevated Cho/Cr
and Lac/Cr ratios in comparison to normal ratios (NAA/
Cr = 0.5, NAA/Cho = 0.2, Lac/Cr ratio = 2.6).The increased Lac/Cr ratio and decreased NAA/Cr repre-
sents a severe stage of HIE (Fig. 4).4. Discussion
Perinatal hypoxia is a vital cause of long-term neurologic com-
plications varying from mild behavioral deﬁcits to severe sei-
zure, mental retardation, and/or cerebral palsy. In an
attempt to determine the cerebral injury and to predict the
Table 8 The mean serum level of NSE in HIE and control groups.
NSE (ng/ml) Stage I Stage II Stage III Control
Mean 28.66 121.72 167.2 12.99
±SD 5.26 33.99 29.64 1.96
Total NSE in HIE 81.7 ± 23.48
P value 0.001*
Stage I & II Stage II &III Stage I & III Stage I & control Stage II & control Stage III & control
Scheﬀe test
0.002* 0.003* 0.001* 0.042* 0.009* 0.001*
* Signiﬁcance P< 0.05
Table 9 Serum level of S100B protein in HIE and control group.
S100 B protein (ng/ml) Stage I Stage II Stage III Control
Mean 0.71 5.82 8.86 0.048
±SD 0.36 1.72 0.54 0.04
Total S100B protein in HIE 3.27 ± 1.05
P value 0.001*
Stage I & Control Stage II & Control Stage III & Control Stage I & II Stage I & III Stage II & III
Scheﬀe test
0.049* 0.001* 0.001* 0.001* 0.002* 0.003*
* Signiﬁcance P< 0.05
Table 10 Sensitivity, speciﬁcity, PPV, NPP of S100B protein, NSE, Lac/Cr, NAA/Cr and NAA/Cho.
S100 B protein NSE Lac/Cr NAA/Cr NAA/Cho
Sensitivity 92.3 91.27 88.2 84 82.5
Speciﬁcity 90.5 87.4 76.9 80.6 83.58
PPV 88.63 85.7 81.63 75.8 81.63
NPV 91.6 79.2 86.3 85.6 79.6
314 A. Noaman et al.neurologic outcome, various investigations have been used as
an adjunct to the clinical examination (13).
In this study the mean time for doing MRS was
14.36 ± 2.28 days. Although it is known that the best time
for MRS is toward the end of ﬁrst week (14).
In the current study 1HMRS result showed that Lac/Cr was
signiﬁcantly higher in the HIE group than the control group.
Also Lac/Cr was signiﬁcantly higher in HIE stage III than
the control group, HIE stages I and II. This signiﬁcant differ-
ence was present between the control group and HIE group as
well as among the control group and different HIE stages
whose Lac/Cr were different.
According to the difference of Lac/Cr, neonates suffered
from HIE divided into three groups; group I where Lac/
Cr < 0.5, group II where Lac/Cr 0.5–1.5 and group III where
Lac/Cr > 1.5.
This result was in agreement with Fan et al. (15) who stud-
ied the correlation of proton MR spectroscopy with MR imag-
ing in full-term neonate with hypoxia-ischemic encephalopathy
and found that severe lesions and poor outcome were most
likely present in the group whose Lac/Cr was greater than
1.5 and they concluded that 1HMRS plays an important role
to diagnose and predict the outcome of HIE. In the current
study the group whose Lac/Cr was greater than 1.5, all babies
died in neonatal period. In addition, severe symptoms andsigns (Sarnat stage III) were presented in group whose Lac/
Cr was greater than 1.5, which conﬁrmed that Lac/Cr was a
sensitive indicator for the outcome.
The elevated brain Lac seen in the injured brain follow-
ing hypoxia–ischemia is probably due to a disruption of
the balance between cytosolic and mitochondrial ATP-pro-
ducing metabolic pathways and up-regulation of cell mem-
brane transporters. A reduction in NAA is related to a
reduction in neuronal/axonal attenuation and viability.
Cho is a putative marker of cellularity and cell turnover
and reduced Cho may be associated with delayed myelina-
tion altered populations of cell types, decreased cellularity
or apoptosis (16).
The increased Lac/Cr ratio in the hours after hypoxic-ische-
mic insult is indirect evidence of impaired cerebral energy
metabolism. The detection of Lac/Cr ratios in the current
study could not be explained by this reason, because the spec-
troscopy examinations were obtained during the second or
third weeks of life. However, there are several mechanisms that
could be implicated in abnormal cerebral energy metabolism in
chronic phases after hypoxic-ischemic brain insult. Among
them, impaired oxidative metabolism due to mitochondrial
damage, reduction in the activity of pyruvate dehydrogenase
complex, and increased activity of microglia with inﬁltrating
phagocytes.
Fig. 1 Five-day old normal full term (39 weeks) male neonate (normal control).
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grouping with clinical Sarnat staging, group I contains 17 pa-
tients (15 patients were present in Sarnat stage I, two patients
were present in Sarnat stage II, group II contains nine patients
(all were present in Sarnat stage II) and group III contains four
patients (all were present in Sarnat stage III).
This correlation was slightly in agreement with Fan et al.
(15) who studied correlation between proton MR spectros-
copy and MR imaging in full term neonates with hypoxicischemic encephalopathy. They found the correlation be-
tween 1HMRS grouping and clinical Sarnat staging as fol-
lows, seven cases of Sarnat stage I and ﬁve cases of Sarnat
stage II were present in 1HMRS group I; eight cases of Sar-
nat stage II, two cases of Sarnat stage l, and ﬁve cases of
Sarnat stage III in group II; while the remaining cases of
Sarnat stage III were present in 1HMRS group III. This little
variation in 1HMRS grouping may be related to the type of
1HMRS machine as their machine was 2.0-Tsuperconductive
Fig. 2 Six-day old female neonate with gestational age of 38 weeks presented clinically with Sarnat stage I.
316 A. Noaman et al.MR system (GE Elscint Prestige) with a circular polarized
head coil and the machine of this study was 1.5-T system
(Signa; GE Medical Systems, Milwauee, WI, USA) with a
quadrature head coil.Lac/Cr measured in the current study was more noticeable
than that reported by previous studies (17,18). This difference
can be explained by type of MRI machine, time at which MRS
study was done and the difference of areas of interest.
Fig. 3 Fifteen-days old male neonate with gestational age of 39 weeks presented clinically with Sarnat stage II.
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Fig. 4 Twelve-day old male neonate with gestational age of 40 weeks presented clinically with Sarnat stage III.
318 A. Noaman et al.Also the present study showed that NAA/Cr was signiﬁ-
cantly lower in the HIE group than control group. Also
NAA/Cr in HIE stage III was signiﬁcantly lower than HIEstages I and II. Also the present study showed that NAA/
Cho in the HIE group was signiﬁcantly lower than control
group and NAA/Cho in HIE stage III was signiﬁcantly lower
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Fan et al. (15) and Cheong et al. (19) who studied proton MR
spectroscopy in neonates with perinatal cerebral hypoxic-
ischemic Injury and they found that comparing the severe/fatal
group with the controls, Lac/NAA, Lac/Cho, and Lac/Cr
peak-area ratios increased and NAA/Cr and NAA/Cho de-
creased and they concluded that metabolite concentrations,
in particular NAA, enhance the prognostic accuracy of cere-
bral 1HMR spectroscopy. NAA was only measurable to dis-
criminate among all (control, normal/mild, and severe/fatal
outcome) groups. However, peak-area ratios are more useful
prognostic indicators than concentration ratios.
These result agreed with Wenzhen et al. (20) whose result
showed that differences in NAA/Cr, NAA/Cho, Lac/Cr, and
GLx-a/Cr values between the HIE and control groups were sig-
niﬁcant. Moreover, the values of Glx-a/Cr and Lac/Cr in the
moderate and severe HIE groups were higher than those in the
mild HIE group. Additionally, as the values of Glx-a/Cr and
Lac/Cr increase and the values of NAA/Cr and NAA/Cho de-
crease, the severity of brain injury inHIEwas aggravated. In this
study MRS machine, glutamine was not measured.
The current study showed that Cho/Cr was signiﬁcantly
higher in the HIE group than control group but Cho/Cr was
statistically insigniﬁcant in different HIE stages when com-
pared to each other. This result disagreed with Cheong et al.
(19) whose result showed that there was an insigniﬁcant differ-
ence between the HIE and control groups as regards Cho/Cr
and also there was no difference between different stages of
HIE when compared with each other and with control.
Cerebral T2 and metabolite ratios: Lac/Cr increasing with
severity of HIE severity and NAA/Cr decreasing with severity
of HIE severity. Elevated brain lactate and diminished NAA
have been documented in patients as early as 18 h after HI. In-
creased brain lactate is thought to reﬂect increased anaerobic
glycolysis secondary to disruption of the mitochondrial electron
transport chain and oxidative phosphorylation; macrophage
inﬁltration or an altered redox state also may contribute NAA
is found exclusively in the central nervous system, predomi-
nantly in neurons; a fall in NAA may represent reduced neuro-
nal and axonal density as cell death proceeds. Our result agreed
with Shanmugalingam et al. (21) who concluded that proton
magnetic resonance spectroscopy was more prognostic than
spin–spin relaxation time, with Lac/NAA as the best measure.
In the current study combined sensitivity, speciﬁcity, PPV
and NPP for biochemical markers, brain metabolites ratios
and Apgar score 1 min were more than sensitivity, speciﬁcity,
PPV and NPP for each item alone showing that sensitivity
for S100B protein was 92.4% and for Lac/Cr was 88.2% while
for both was increased to 95.86%. While sensitivity for S100B
protein was 92.4% and for NAA/Cr was 84 while for both was
increased to 96.36% and sensitivity for NSE was 91.27 and for
Lac/Cr was 88.2% while for both was increased to 93.3%. Sen-
sitivity for NSE was 91.27 and for NAA/Cr was 84% while for
both was increased to 94.52%.
In the current study the mean serum level of S100B protein
was signiﬁcantly higher in the HIE group than control group.
And also S100B protein was signiﬁcantly higher in HIE stage
III than control, HIE stage I and stage II. This reﬂects the
importance of S100B protein as a marker not only for diagno-
sis of HIE but also for assessing the severity of hypoxic insult.
This result agreed with that of Murabayashi et al. (22) who
studied the kinetic of serum S100B protein in newborns withintracranial lesion and concluded that serum S100B level is a
useful marker of acute perinatal brain damage, and is particu-
larly valuable for fetal distress. In newborns with birth asphyx-
ia, serum S100B levels serve as a biochemical marker of HIE.
Also Maschmann et al. (23) reported increased serum S100
levels in newborns with HIE signs due to perinatal acidosis and
Nagdyman et al. (24) who reported that serum S100b protein
level was signiﬁcantly higher in infants with moderate or severe
HIE than in infants with no or mild HIE.
Qian et al. (25) examined the levels of S100b protein in the
umbilical artery blood and found that S100b concentrations
were signiﬁcantly higher in the HIE group compared to con-
trols and that there was a signiﬁcant difference between the
moderate or severe HIE and mild HIE groups.
On the other hand Osorio et al. (26) found that there was
no statistical difference of serum S100b protein level between
different HIE stages. This difference may refer to the sample
size or time at which S100b protein was done.
In the present study the mean serum level of NSE was sig-
niﬁcantly higher in the HIE group than control and it was sig-
niﬁcantly higher in HIE stage III than the control group, HIE
stage I and stage II.
These results agreed with those of Celtik et al. (27) who
demonstrated that serum NSE concentrations of infants with
stage III HIE were signiﬁcantly higher than those in stages I
and II HIE.
In contrast to this study, Nagdyman et al. (28) reported no
signiﬁcant difference in serum NSE levels between infants with
no or mild and moderate or severe HIE, 2 and 6 h after birth
but there was a signiﬁcant difference at 12 and 24 h age.
Also this result disagreed with Tekgul et al. (29) who stated
that there was no signiﬁcant difference in serum NSE concen-
trations between the HIE groups while the concentration of
cerebrospinal ﬂuid NSE was signiﬁcantly higher in infants with
moderate to severe HIE as compare with the mild HIE group.5. Conclusions
Magnetic resonance spectroscopy is used to detect the meta-
bolic and biochemical proﬁle in brain areas. Proton magnetic
resonance spectroscopy of the brain is useful whenever bio-
chemical and metabolic assessments may be necessary, such
as inborn error of metabolism and hypoxic encephalopathy:
The aim of this work is to assess S100B protein, Neuron
speciﬁc enolase and magnetic resonance spectroscopy as bio-
chemical and imaging ﬁndings in neonatal hypoxic ischemic
encephalopathy.
This study was conducted on 30 full-term neonates suffer-
ing from HIE who were attendants of the Neonatology Unit
of Pediatric Department of Tanta University Hospital and
10 healthy full-term neonates served as a control group.
1HMRS group I contained 17 patients (15 patients were
present in Sarnat stage I and two patients were present in Sar-
nat stage II). Group II contained nine patients (all patients
were present in Sarnat stage II). Group III contained four pa-
tients (all patients were present in Sarnat stage III).
 Serum level of S100B protein and NSE were signiﬁcantly
higher in the HIE group than the control group Also serum
level of S100B protein and NSE in HIE stage III was signif-
icantly higher than control, HIE stage I and stage II.
320 A. Noaman et al. 1HMRS results showed:
– Lac/Cr was signiﬁcantly higher in the HIE group than con-
trol group. Also Lac/Cr was signiﬁcantly higher in HIE
stage III than HIE stages I, II and stage III.
– NAA/Cr was signiﬁcantly lower in the HIE group than con-
trol group. Also NAA/Cr was signiﬁcantly lower in HIE
stages I, II and III than the control group.
– NAA/Cho was signiﬁcantly lower in the HIE group than
control group. Also NAA/Cho was signiﬁcantly lower in
HIE stages I, II and III than the control group.
– Cho/Cr in the HIE group was signiﬁcantly higher than the
control group. Also Cho/Cr in HIE stage III was signiﬁ-
cantly higher than the control and HIE stage I. While no
difference between HIE stage III and stage II.
In MRS peak metabolites ratios, the highest sensitivity was
for Lac/Cr 88.2 versus 84 and 82.5 for NAA/Cr and NAA/
Cho, respectively. While the highest speciﬁcity was for NAA/
Cho 83.58 versus 76.9 and 80.6 for Lac/CR and NAA/Cr,
respectively. The highest PPV was for Lac/Cr and NAA/Cho
81.63 versus 75.8 for NAA/Cr. Lastly NPP was the highest
for Lac/Cr 86.3 versus 85.6 and 79.6 for NAA/Cr and NAA/
Cho, respectively.
As regards biochemical marker the highest sensitivity and
speciﬁcity observed for S100B protein with sensitivity and
speciﬁcity of 92.3% and 90.5%, respectively versus 91.2%
and 87.4% to NSE. PPV and NPP also were higher for
S100B protein than those of NSE 88.9% and 91.6% versus
85.7% and 79.2%, respectively.References
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